Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Interview · October 03, 2013

Honing Precision: The Neoadjuvant Approach

Axel Grothey MD
Lee Schwartzberg MD, FACP

 

 Save  Recommend
 Share

Additional Info

  1. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women With Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial. Lancet Oncol. 2012;13(1):25-32.

  2. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab Plus Trastuzumab in Combination With Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients With HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-2284.

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Lee Schwartzberg MD, FACP

Further Reading

Most Read This Week

Recently Updated